
Ronald C. Renaud has served as the chief financial officer of
Idenix Pharmaceuticals, Inc. since June 2007. He has served additionally as
Chief Business Officer since June 2010. He is responsible for all finance,
treasury, investor relations and business development functions. Mr.
Renaud brings a unique mix of skills to this role with his finance experience
at public biotechnology companies and on Wall Street, as well as his science
background. Prior to joining Idenix, Mr. Renaud served as chief
financial officer of Keryx Biopharmaceuticals. In this role he was responsible
for the strategic planning and development of the finance function to support
the company’s growth and its late-stage product candidate development. Prior to
his position at Keryx, he spent several years as a senior biotechnology equity
analyst for leading investment banks including Bear Stearns, Schwab SoundView
and JP Morgan. Additional industry experience includes Mr. Renaud's more
than five years at Amgen Inc., where he held positions in clinical research,
investor relations and finance.
Mr. Renaud holds a Masters in Business Administration from the Marshall School
of Business at the University of Southern California and a Bachelor of Arts
from St. Anselm College in Manchester, NH.